Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

A collaborative effort across 14 clinical centers in Canada and Australia reports that pregnant women with type 1 diabetes ...

In a letter to CMS Administrator Mehmet Oz, diabetes caucus leaders raised concerns that the agency’s proposals will reduce ...

Glucotrack, Inc. (Nasdaq: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

As people around the world seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by ...

Tidepool, a 501(c)(3) nonprofit leader in diabetes software, today announced a strategic collaboration with URA, maker of the world's leading smart ring, to support a groundbreaking dataset intended ...